SNCA and multiple system atrophy: Anotherpromising development is the use of the β-lactum antibiotic ceftriaxone as atherapeutic agent to block α-synuclein aggregation [128], although the macrocyclic antibiotic rifampicin has not beensuccessful in MSA [129].